MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology.
Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma
- EurekAlert
- 23. 7 2021 (06:00)